Estrogen receptor actions on vascular biology and inflammation: Implications in vascular pathophysiology

Climacteric

Volumn 12, Issue SUPPL. 1, 2009, Pages 12-17

  Arnal, J F ^a   Laurell, H ^a   Fontaine, C ^a   Billon, A ^a   Calippe, B ^a   Lenfant, F ^a   Gourdy, P ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ESTROGEN RECEPTORS; ESTROGENS; THROMBOSIS

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NITRIC OXIDE; PROSTACYCLIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MEMBRANE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM; GENETIC TRANSCRIPTION; IMMUNE SYSTEM; INFLAMMATION; LIPID STORAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASCULAR BIOLOGY; ANIMAL; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MICE; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 73949142875     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130902820006     Document Type: Article

References (29)

1. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61 (Pubitemid 26269944)
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13 (Pubitemid 28502636)
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
4. Hodgin J, Maeda N. Estrogen and mouse models of atherosclerosis. Endocrinology 2002;143:4495-501
5. Clarkson TB, Appt SE. Controversies about HRT - lessons from monkey models. Maturitas 2005;51:64-74 (Pubitemid 40692601)
6. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7 (Pubitemid 40807497)
7. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterolclamped rabbits. Circulation 1999;100:1727-33 (Pubitemid 29485256)
8. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81
9. Elhage R, Gourdy P, Huc X, et al. The atheroprotective effect of 17-estradiol depends on complex interactions in adaptive immunity. Am J Pathol 2005;167:267-74 (Pubitemid 40884787)
10. Ghisletti S, Meda C, Maggi A, Vegeto E. 17bestradiol inhibits inflammatory gene expression by controlling NF-k B intracellular localization. Mol Cell Biol 2005;25:2957-68 (Pubitemid 40464301)
11. Calippe B, Douin-Echinard V, Laffargue M, et al. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. J Immunol 2008;180:7980-8
12. Soucy G, Boivin G, Labrie F, Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol 2005;174:6391-8 (Pubitemid 40663832)
13. Maret A, Coudert JD, Garidou L, et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003;33:512-21 (Pubitemid 36267617)
14. Gourdy P, Araujo LM, Zhu R, et al. Relevance of sexual dimorphism to regulatory T cells: estradiol promotes IFN-g production by invariant natural killer T cells. Blood 2005;105:2415-20 (Pubitemid 40387040)
15. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res 2000;87:956-60
16. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the a-, but not b-, estrogen receptor. Circ Res 2002;90:413-19 (Pubitemid 34633910)
17. Elhage R, Bayard F, Richard V, et al. Prevention of fatty streak formation of 17b-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation 1997;96:3048-52 (Pubitemid 27500107)
18. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-7 (Pubitemid 39627863)
19. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90:11162-6 (Pubitemid 23354389)
20. Pendaries C, Darblade B, Rochaix P, et al. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci USA 2002;99:2205-10 (Pubitemid 34169039)
21. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000;127:4277-91
22. Pare G, Krust A, Karas RH, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002;90:1087-92 (Pubitemid 34627907)
23. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003;100:4807-12 (Pubitemid 36457810)
24. Billon-Galés A, Fontaine C, Filipe C, et al. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17b-estradiol. Proc Natl Acad Sci USA 2009;106:2053-8
25. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor alpha is a major mediator of 17b-estradiol's atheroprotective effects on lesion size in Apoe-/-mice. J Clin Invest 2001;107:333-40 (Pubitemid 32157965)
26. Kos M, Denger S, Reid G, Korach KS, Gannon F. Down but not out? A novel protein isoform of the estrogen receptor alpha is expressed in the estrogen receptor alpha knockout mouse. J Mol Endocrinol 2002;29:281-6 (Pubitemid 36024544)
27. Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci 2006;1089:424-30 (Pubitemid 47092056)
28. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
29. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)